Home » Stocks » resTORbio

resTORbio, Inc. (TORC)

Sep 16, 2020 - Stock symbol was changed to ACET
Stock Price: $15.40 USD 13.12 (575.44%)
Updated Sep 16, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 561.39M
Revenue (ttm) n/a
Net Income (ttm) -65.98M
Shares Out 36.45M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 16, 2020
Last Price $15.40
Previous Close $2.28
Change ($) 13.12
Change (%) 575.44%
Day's Open 2.38
Day's Range 14.56 - 16.09
Day's Volume 101,708
52-Week Range 0.86 - 16.09

More Stats

Market Cap 561.39M
Enterprise Value 490.26M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 36.45M
Float 21.50M
EPS (basic) -1.92
EPS (diluted) -1.81
FCF / Share -1.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 560,879
Short Ratio 0.82
Short % of Float 2.61%
Beta 2.43
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.09
Revenue n/a
Operating Income -67.63M
Net Income -65.98M
Free Cash Flow -67.90M
Net Cash 71.13M
Net Cash / Share 1.95
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -38.47%
ROE -66.75%
ROIC -179.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

Current: $15.40
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-85.46-39.71-18.88
Net Income-82.74-37.61-33.78
Shares Outstanding34.3126.444.01
Earnings Per Share-2.41-1.42-8.42
Operating Cash Flow-73.68-35.45-10.99
Capital Expenditures-0.27-0.36-0.04
Free Cash Flow-73.95-35.81-11.03
Cash & Equivalents91.7210853.35
Net Cash / Debt91.7210853.35
Book Value81.70104-31.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name resTORbio, Inc.
Country United States
Employees 10
CEO Chen Schor

Stock Information

Ticker Symbol TORC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TORC
IPO Date January 26, 2018


resTORbio, a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. has collaboration with TrialSpark to investigate RTB-101 for COVID-19 on the Project Covalence platform. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.